September 4, 2024 01:21 PM EDT

With $200M investment, Novartis builds out radioligand manufacturing at two sites

Katherine Lewin

News Reporter

Novartis is putting $200 million into its radioligand therapy manufacturing capabilities with a new site in California and the expansion of an existing site in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With $200M investment, Novartis builds out radioligand manufacturing at two sites

Katherine Lewin

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

Ex-Kite leaders step in at Kyverna as CEO exits after landing year's second-biggest IPO

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

BioNTech rolls out Phase 2 lung cancer data as VEGF bispecifics take center stage

Immatics loses Bristol Myers' support on Phase 1 bispecific T cell engager

Breaking down silos with a new quantitative approach to drug development

With $200M in­vest­ment, No­var­tis builds out ra­di­oli­gand man­u­fac­tur­ing at two sites

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

With $200M investment, Novartis builds out radioligand manufacturing at two sites